Back to School: How biopharma can reboot drug development. Access exclusive analysis here

J591: Phase I

BZL said that in a 33-patient Phase I study, J591 demonstrated

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE